Sarcoidosis

  1. Revenga Martínez, M.
  2. Blázquez Cañamero, M.A.
  3. Llop Vilatella, M.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Any de publicació: 2017

Sèrie: 12

Número: 27

Pàgines: 1560-1573

Tipus: Article

DOI: 10.1016/J.MED.2017.02.002 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Medicine: Programa de Formación Médica Continuada Acreditado

Objectius de Desenvolupament Sostenible

Resum

Introduction Sarcoidosis is a multisystemic disease affecting young adults with slight female predominance. Usually has bilateral hilar lymphadenopathy, pulmonary infiltrates, and eye and skin lesions. From an asymptomatic state to a chronic condition, with the possibility of causing severe clinical sequelae, deterioration of the quality of life, and even death. Aetiopathogenesis Of unknown aetiopathogenesis, will suggest that the exposure to one or several antigens, environmental, infectious or genetic, triggers an abnormal immune response in a genetically susceptible host. Diagnosis Definitive diagnosis of sarcoidosis requires a compatible clinical-radiological manifestations, histological evidence of non-caseating granulomas and exclusion of other granulomatous diseases. Treatment The basis of the treatment are the corticosteroids. Immunosuppressants may be used, as savers of corticosteroids, or second-line treatment, given its ineffectiveness, side effects, or the need for prolonged treatment. And as a third option, biological agents and even organ transplant.

Referències bibliogràfiques

  • Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-65.
  • Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155-67.
  • Brito-Zerón P, Sellarés J, Bosch X, Hernández F, Kostov B, Sisó-Almirall S. Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity related differences. Clin Exp Rheumatol. 2016;34(3): 380-8.
  • Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of Sarcoidosis 1946-2013: A population-based. Study. Mayo Clin Proc. 2016;91(2):183-8.
  • Newman KL, Newman LS. Occupational causes of sarcoidosis. Curr Opin Allergy Clin Immunol. 2012;12(2):145-50.
  • Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med. 2011;53(9):966-74.
  • Celada LJ, Hawkins C, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Clin Chest Med. 2015;36(4): 561-8.
  • Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA. Familial aggregation of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085-91.
  • Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391-9.
  • Bonham CA, Strek ME, Patterson KC. From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis. Curr Opin Pulm Med. 2016;22(5):484-91.
  • Jeny F, Bouvry D, Freynet O, Soussan M, Brauner M, Planes C. Management of sarcoidosis in clinical practice. Eur Respir Rev. 2016;25(140):141-50.
  • Valeyre D, Bernaudin JF, Jeny F, Duchemann B, Freynet O, Planès C, et al. Pulmonary Sarcoidosis. Clin Chest Med. 2015;36(4):631-41.
  • Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165-72.
  • Guidry C, Fricke RG, Ram R, Pandey T, Jambhekar K. Imaging of sarcoi-dosis: A contemporary review. Radiol Clin North Am. 2016;54(3):519-34.
  • Ors F, Gumus S, Aydogan M, Sari S, Verim S, Deniz O. HRCT findings of pulmonary sarcoidosis; relation to pulmonary function tests. Multidiscip Respir Med. 2013;8(1):8.
  • Silva M, Nunes H, Valeyre D, Sverzellati N. Imaging of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):45-53.
  • Costabel U, Bonella F, Ohshimo S, Guzman J. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med. 2010;31(4):404-8.
  • Rao DA, Dellaripa PF. Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am. 2013;39(2):277-97.
  • Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(1):26-33.
  • Herbort CP, Rao NA, Mochizuki M, Members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160-9.
  • Oleñik A, Gonzalo-Suárez B, Revenga M, Roldán E, Vázquez M, Muñoz-Negrete FJ. Use of aqueous humor and flow cytometry in ocular sarcoi-dosis diagnosis. Ocul Immunol Inflamm. 2016;15:1-5.
  • Sánchez M, Haimovic A, Prystowsky S. Sarcoidosis. Dermatol Clin. 2015; 33(3):389-416.
  • Kobak S. Sarcoidosis: a rheumatologist’s perspective. Ther Adv Musculoskelet Dis. 2015;7(5):196-205.
  • Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-21.
  • Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. J Neurol. 2015;262(2):258-67.
  • Syed U, Alkhawam H, Bakhit M, Companioni RA, Walfish A. Hepatic sarcoidosis: pathogenesis, clinical context, and treatment options. Scand J Gastroenterol. 2016;51(9):1025-30
  • La Rochelle JC, Coogan CL. Urological manifestations of sarcoidosis. J Urol. 2012;187(1):18-24.
  • Wendling D, Prati C. Paradoxical effects of anti-TNF-D agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(1):159-69.
  • Govender P, Berman JS. The diagnosis of sarcoidosis. Clin Chest Med. 2015;36(4):585-602.
  • Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoim-mun Rev. 2014;13(4-5):383-7.
  • Gungor S, Ozseker F, Yalcinsoy M, Akkaya E, Can G, Eroglu H, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174-9.
  • Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. Expert Rev Clin Immunol. 2016:1-18.
  • Kurdziel KA. The panda sign. Radiology. 2000;215(3):884-5.
  • Promteangtrong C, Salavati A, Cheng G, Torigian DA, Alavi A. The role of positron emission tomography computed tomography/magnetic resonance imaging in the management of sarcoidosis patients. Hell J Nucl Med. 2014;17(2):123-35.
  • Carmona EM, Kalra S, Ryu JH. Pulmonary sarcoidosis: diagnosis and treatment. Mayo Clin Proc. 2016;91(7):946-54.
  • Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;7:325-38.
  • Sah BP, Goyal S, Iannuzzi MC. Novel pharmacotherapy of sarcoidosis. Pharmacol Ther. 2016;157:1-9.
  • Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817-25.
  • Shetty AK, Gedalia A. Childhood sarcoidosis: A rare but fascinating disorder. Pediatr Rheumatol Online J. 2008;6:16.
  • Wouters CH, Maes A, Foley KP, Bertin J, Rose CD. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J. 2014;12:33.
Fuente de los datos: Dialnet